Diversify Advisory Services LLC purchased a new stake in shares of Novanta Inc. (NASDAQ:NOVT - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,392 shares of the technology company's stock, valued at approximately $2,449,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in NOVT. Summit Creek Advisors LLC bought a new position in Novanta in the 2nd quarter worth approximately $6,350,000. Deutsche Bank AG bought a new stake in shares of Novanta in the second quarter valued at approximately $14,992,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Novanta in the second quarter worth $788,000. OneDigital Investment Advisors LLC acquired a new stake in shares of Novanta in the second quarter worth $947,000. Finally, Global Retirement Partners LLC bought a new position in Novanta during the second quarter worth $446,000. 98.35% of the stock is owned by institutional investors and hedge funds.
Novanta Trading Down 6.9%
Shares of NOVT stock opened at $157.11 on Wednesday. Novanta Inc. has a 52-week low of $98.27 and a 52-week high of $176.38. The stock has a market cap of $5.94 billion, a price-to-earnings ratio of 100.71 and a beta of 1.68. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.79 and a current ratio of 4.57. The firm has a fifty day moving average of $154.33 and a 200-day moving average of $143.01.
Novanta (NASDAQ:NOVT - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The technology company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.06. The company had revenue of $265.81 million during the quarter, compared to the consensus estimate of $262.30 million. Novanta had a net margin of 6.00% and a return on equity of 10.83%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.76 EPS. Novanta has set its FY 2026 guidance at 3.680-3.740 EPS and its Q3 2026 guidance at 0.950-1.000 EPS. On average, equities research analysts forecast that Novanta Inc. will post 3.7 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently commented on NOVT shares. Zacks Research upgraded shares of Novanta from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 14th. Robert W. Baird set a $194.00 price target on shares of Novanta in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Novanta from a "hold" rating to a "buy" rating in a report on Sunday, August 9th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Novanta in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Novanta presently has an average rating of "Buy" and an average target price of $194.00.
Check Out Our Latest Stock Analysis on NOVT
Insider Buying and Selling
In other news, CEO Matthijs Glastra sold 6,500 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $161.13, for a total value of $1,047,345.00. Following the sale, the chief executive officer directly owned 29,761 shares in the company, valued at approximately $4,795,389.93. This represents a 17.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.20% of the stock is currently owned by corporate insiders.
About Novanta
(
Free Report)
Novanta, Inc NASDAQ: NOVT is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta's product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta's Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novanta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novanta wasn't on the list.
While Novanta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.